A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(70 sites)

United States

Banner Sun Health Research Institute, Sun City, Arizona

University of Arkansas, Little Rock, Arkansas

Neuro-Pain Medical Center, Fresno, California

University of California, Irvine, Irvine, California

University of California, Los Angeles, Los Angeles, California